Reversal of mitomycin C resistance by overexpression of bioreductive enzymes in Chinese hamster ovary cells

Cancer Research

Volumn 61, Issue 21, 2001, Pages 7770-7776

  Baumann, Raymond P ^a   Hodnick, William F ^a   Seow, Helen A ^a   Belcourt, Michael F ^a   Rockwell, Sara ^a   Sherman, David H ^b   Sartorelli, Alan C ^a  

^a YALE CANCER CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOMYCIN C; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE;

ANIMAL CELL; ANTIBIOTIC RESISTANCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG ACTIVATION; DRUG SENSITIVITY; ENZYME ACTIVITY; GENETIC TRANSFECTION; IMMUNOBLOTTING; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REDUCTION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BACTERIAL PROTEINS; BIOTRANSFORMATION; CELL HYPOXIA; CHO CELLS; CRICETINAE; DRUG RESISTANCE, NEOPLASM; MITOMYCIN; NAD(P)H DEHYDROGENASE (QUINONE); NADPH-FERRIHEMOPROTEIN REDUCTASE; OXIDOREDUCTASES; OXYGEN; TRANSFECTION;

EID: 0035503006     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Antitumor antibiotics
2. Mitomycin, a new antibiotic from Streprotomyces
3. Exploring the mechanistic aspects of mitomycin antibiotic bioactivation in Chinese hamster ovary cells overexpressing NADPH:cytochrome c (P-450) reductase and DT-diaphorase
4. DT-diaphorase
5. Bioreductive activation of mitomycin C by DT-diaphorase
6. Metabolism of bioreductive antitumor compounds by purified rat and human DT-diaphorases
7. Metabolism of mitomycin C by DT-diaphorase: Role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells
8. DT-diaphorase: Possible roles in cancer chemotherapy and carcinogenesis
9. Overexpression of DT-diaphorase in transfected NIH 3T3 cells does not lead to increased anticancer quinone drug sensitivity: A questionable role for the enzyme as a target for bioreductively activated anticancer drugs
10. Expression of human NAD(P)H:Quinone oxidoreductase (DT-diaphorase) in Chinese hamster ovary cells: Effect on the toxicity of antitumor quinones
11. DT-diaphorase as a critical determinant of sensitivity to mitomycin C in human colon and gastric carcinoma cell lines
12. A unique cytosolic activity related but distinct from NQO1 catalyzes metabolic activation of mitomycin C
13. Reductive activation of mitomycin C metabolites catalyzed by NADPH-cytochrome P-450 reductase and xanthine oxidase
14. Bioactivation of mitomycin C by xanthine dehydrogenase from EMT6 mouse mammary carinoma tumors
15. Pharmacology of mitomycin C: III. In vitro metabolism by rat liver
16. Metabolic activation of mitomycin C by liver microsomes and nuclei
17. Reductive activation of mitomycin C by NADPH:cytochrome b 5 reductase
18. Mechanistic aspects of mitomycin C activation by flavoprotein transhydrogenases
19. Mitomycins and porfiromycin: Chemical mechanism of activation and cross-linking of DNA
20. Cytotoxicity and DNA crosslinks produced by mitomycin analogs in aerobic and hypoxic EMT6 cells
21. Mechanisms and clinical significance of multidrug resistance
22. Mechanisms of resistance to alkylating agents in drug resistance
23. Mitomycin resistance in mammalian cells expressing the bacterial mitomycin C resistance protein MCRA
24. Cloning and analysis of a locus (mcr) involved in mitomycin C resistance in Strepromyces lavendulae
25. Inducible synthesis of the mitomycin C resistance gene product (MCRA) from Streptomyces lavendulae
26. Microbial resistance to mitomycins involves a redox relay mechanism
27. Measurement of dicumarol-sensitive NADPH: (Menadone-cytochrome c) Oxidoreductase activity results in an artifactual assay of DT-diaphorase in cell sonicates
28. Differential toxicity of mitomycin C and porfiromycin to aerobic and hypoxic Chinese hamster ovary cells overexpressing human NADPH:cytochrome c (P-450) reductase
29. Bioactivation of mitomycin antibiotics by aerobic and hypoxic Chinese hamster ovary cells overexpressing DT-diaphorase
30. Mutants of Chinese hamster ovary (CHO) cells with altered colcemid binding affinity
31. Effect of BMY25282, a mitomycin C analogue. in mitomycin C-resistant human colon cancer cells
32. Circumvention of deficient activation in mitomycin C-resistant human colonic carcinoma cells by the mitomycin C analogue BMY25282
33. The role of NADPH:quinone oxidoreductase in mitomycin C- and porfiromycin-resistant HCT 116 human colon-cancer cells
34. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: Characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity
35. Isolation of Chinese hamster ovary cell mutants deficient in excision repair and mitomycin C bioactivation
36. Chinese hamster ovary cell lines resistant to mitomycin C under aerobic but not hypoxic conditions are deficient in DT-diaphorase
37. Decreased NADPH: Cytochrome P-450 reductase activity and impaired drug activation in a mammalian cell line resistant to mitomycin C under aerobic but not hypoxic conditions
38. Deficient activation by a human cell strain leads to mitomycin resistance under aerobic but not hypoxic conditions
39. DNA-mediated transfer of a human gene that confers resistance to mitomycin C
40. Increased sensitivity of quinone resistant cells to mitomycin C
41. Characterization of L5178Y murine lymphoblasts resistant to quinone antitumor agents
42. Characterization of a human bladder cancer cell line selected for resistance to mitomycin C
43. Mechanism of differential sensitivity of human bladder cancer cells to mitomycin C and its analogue
44. Effect of deficiencies in DNA repair on the toxicity of mitomycin C and porfiromycin to CHO cells under aerobic and hypoxic conditions
45. Mitomycin C-DNA adducts generated by DT-diaphorase. Revised mechanism of the enzymatic reductive activation of mitomycin C
46. Generation of reactive oxygen radicals through bioactivation of mitomycin antibiotics